Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Liquid Biopsies 2019

Shan Wang's Biography

Shan Wang, Leland T. Edwards Professor in the School of Engineering, Stanford University

Dr. Wang is the Leland T. Edwards Professor in the School of Engineering, Stanford University. He is a Professor and Associate Chair of Materials Science & Engineering and jointly a Professor of Electrical Engineering, and by courtesy, a Professor of Radiology (Stanford School of Medicine). He directs the Center for Magnetic Nanotechnology, and is a co-Principal Investigator of the Center for Cancer Nanotechnology Excellence for Translational Diagnostics (CCNE-TD) at Stanford University. He has over 270 publications, and holds 59 issued or pending patents in the areas of magnetic nanotechnology and information storage, biosensors, spintronics, and power management. He was named an inaugural Fred Terman Fellow, and he was elected a Fellow of the Institute of Electrical and Electronics Engineers (IEEE) and a Fellow of American Physical Society (APS) for his seminal contributions to magnetic materials and nanosensors. His team won the Grand Challenge Exploration Award from Gates Foundation (2010), the XCHALLENGE Distinguished Award (2014), and the Bold Epic Innovator Award from the XPRIZE Foundation (2017). He cofounded three high-tech startups in Silicon Valley, including MagArray, Inc. and Flux Biosciences, Inc. Dr. Wang obtained his PhD in Electrical and Computer Engineering from Carnegie Mellon University in 1993, MS in Physics from Iowa State University in 1988, and BS in Physics from the University of Science and Technology of China in 1986.

Shan Wang Image

Nanodiagnostic Tool for Comprehensive Assessment of Cancer in Blood

Wednesday, 27 March 2019 at 17:30

Add to Calendar ▼2019-03-27 17:30:002019-03-27 18:30:00Europe/LondonNanodiagnostic Tool for Comprehensive Assessment of Cancer in BloodLiquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island,

Blood borne biomarkers, such as secreted proteins, circulating tumor DNA (ctDNA) and circulating tumor cell (CTC), have garnered much attention as minimally invasive cancer biomarkers for the “liquid biopsy” of tumors over the past decade. In this talk, we will describe three magnetic-nanoparticle-based diagnostic tools that have been used to assess cancer in peripheral blood successfully: 1) Stanford spin-off MagArray Inc. has launched REVEAL, a cancer-specific blood test that may aid clinicians in characterizing indeterminate pulmonary nodules (4-30mm) in current smokers aged 25-85. The REVEAL Score is calculated using an algorithm based on the measurement of 3 clinical factors and 3 blood proteins associated with the presence of lung cancer. The assay is optimized to rule out lung cancer with a negative predictive value (NPV) of = 95%.  2) We have developed sequence-specific capture of hypermethylated or mutated genes of interest from cfDNA for early detection of NSCLC and colorectal cancer (CRC). With downstream analysis of PCR products on giant magnetoresistive (GMR) biosensors and high-resolution melt analysis for a highly multiplexable assay, we have achieved a sensitivity of 0.01% mutant/methylated allele fractions. Our optimized assay has the ability to detect down to 16 pg (~4 genome equivalents) of hypermethylated DNA spiked-in to 3.5 mL of plasma. 3) We have utilized the MagSifter and immunocytochemistry combined with automated image analysis and machine learning techniques (random forest, transfer learning) for the enumeration and diagnosis/prognosis of NSCLC derived CTCs in patient samples, which are well suited for therapy selection and monitoring.

Add to Calendar ▼2019-03-27 00:00:002019-03-29 00:00:00Europe/LondonLiquid Biopsies 2019Liquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island,